Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $110.03M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 1.79M
Average 7.64M
CMPX Interest Income
Income earned on cash, deposits, and investments held by the company.
Compass Therapeutics, Inc.NASDAQ: CMPX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $1.98M rose 48.7% year over year, ahead of the +5.2% change in trailing-twelve-month interest income. Sequentially, it fell 12.8% from the prior quarter. Over 3 fiscal years it compounded at +39.1% a year.
Context
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +48.7% holds above the trailing-twelve-month pace of +5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 6.35M USD
- Year-over-year change
- -13.0%
- 4-year CAGR
- +284.7%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.35M | -13.0% |
| FY2024 | 2024-12-31 | 7.3M | -7.6% |
| FY2023 | 2023-12-31 | 7.9M | +234.7% |
| FY2022 | 2022-12-31 | 2.36M | +8037.9% |
| FY2021 | 2021-12-31 | 29K | — |
Interest Income vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's LTM Mar 2026 interest income of $7M is the 5th highest of the 11 companies compared; the peer median is $4.98M.
- Its year-over-year change of +5.2% is the 4th highest of 9, against a peer median of -16.8%.
- Over three fiscal years its annual growth of +39.1% compares with a peer median of +59.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $24.93M | -32.8% | +70.4% | 39.3% | |
| LTM Mar 2026 | $18.76M | -30.2% | +96.3% | 21.3% | |
| LTM Mar 2026 | $16.69M | +85.2% | +7.6% | 168.7% | |
| LTM Dec 2025 | $9.64M | — | — | 8.3% | |
| LTM Mar 2026 | $7M | +5.2% | +39.1% | — | |
| LTM Mar 2026 | $6.23M | -50.7% | +63.0% | 8.9% | |
| LTM Mar 2026 | $3.72M | +305.2% | +420.1% | — | |
| LTM Mar 2026 | $2.03M | +17.4% | +7.6% | 3.7% | |
| LTM Mar 2026 | $483K | -3.4% | -13.0% | 10.8% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$525K | -125.8% | +56.5% | — | |
| Peer median (excluding CMPX) | $4.98M | -16.8% | +59.7% | 10.8% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 850K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.47M |
| Gross Profit | 0 | 0 | 0 | 850K | (1.47M) |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 20.34M | 30M | 38.12M | 42.34M | 55.97M |
| Selling, General & Admin | 10.93M | 11.66M | 12.24M | 15.13M | 16.87M |
| Operating Expenses | 81.88M | 41.66M | 50.36M | 57.48M | 71.37M |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | 1.47M |
| EBITDA | (80.19M) | (34.96M) | (40.6M) | (47.62M) | (65.02M) |
| EBITDA Margin | — | — | — | -5602.6% | — |
| Operating Income | (81.88M) | (41.66M) | (50.36M) | (56.63M) | (72.84M) |
| Operating Margin | — | — | — | -6661.8% | — |
| Interest Income | 29K | 2.36M | 7.9M | 7.3M | 6.35M |
| Interest Expense | 370K | 2.36M | 0 | 0 | 0 |
| Other Income / Expenses | (299K) | 2.43M | 7.87M | 7.25M | 6.35M |
| Income Before Tax | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Pre-Tax Margin | — | — | — | -5808.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Net Margin | — | — | — | -5808.8% | — |
| EPS (Basic) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| EPS (Diluted) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| Weighted Avg Shares | 62.87M | 105.19M | 127.03M | 137.11M | 157.7M |
| Weighted Avg Shares (Diluted) | 62.87M | 105.19M | 127.03M | 137.11M | 157.7M |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.